PROPULSID
LOE ApproachingNDAORALTABLET
Approved
Jul 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROPULSID (brand name for cisapride) is an oral small-molecule prokinetic agent approved in 1993 for gastrointestinal motility disorders. It enhances gastric contractions and accelerates gastric emptying. The drug is primarily indicated for patients with gastroesophageal reflux disease (GERD) and related motility conditions.
LOE Approaching
With LOE approaching and moderate competitive pressure (30), brand team roles are likely focused on maximizing remaining patent value and managing market contraction.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PROPULSID currently shows zero linked job openings, reflecting its LOE-approaching stage. Career opportunities on this product are limited and will continue to decline, making it a transitional assignment rather than a growth platform.
Brand ManagerProduct Manager
Worked on PROPULSID at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.